Everybody’s getting ready for the annual social sector lollapalooza in Oxford, and there have never been so many sessions with the word “scale” in the title. There seems to be a collective recognition ...

Dog N Suds locations in the Lafayette area are opening for their 70th season on Feb. 23. General Manager Joe Davenport credits the restaurant's longevity to consistency, quality and community support.

Reload is a proven powered land development platform with a multi-gigawatt pipeline purpose built for hyperscale data center growth. The acquisition builds on recent progress in Scale’s growing data ...

In case you've faced some hurdles solving the clue, Exams graded on a 5-point scale, we've got the answer for you. Crossword puzzles offer a fantastic opportunity to engage your mind, enjoy leisure ...

With a late-stage miss reported for its prospective social anxiety disorder (SAD) treatment fasedienol, Vistagen’s chances at an FDA approval in the indication are looking slimmer. That said, the ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in anxiety as measured by SUDS scores compared to placebo Favorable safety and tolerability data were ...

Vistagen Inc. (NASDAQ: VTGN) stock is plunging on Wednesday, with a session volume of 20.91 million compared to the average volume of 711,000, as per data from Benzinga Pro. The clinical-stage ...

Fasedienol did not statistically significantly improve anxiety compared with placebo in the phase 3 PALISADE-3 trial for social anxiety disorder. Topline data were announced from a phase 3 trial ...

Five months after Scale AI's high-profile founder joined Meta in a blockbuster deal, the startup's CFO is trying to show that the company remains on a growth trajectory. "People mischaracterize this ...

Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...

BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for ...